Tabor Asset Management LP bought a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 36,195 shares of the company's stock, valued at approximately $506,000. Tabor Asset Management LP owned 0.25% of Inhibrx Biosciences as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of the business. Sanofi acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $17,832,000. Walleye Capital LLC acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $8,932,000. Slotnik Capital LLC acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $5,975,000. Millennium Management LLC acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $3,979,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $3,930,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.
Inhibrx Biosciences Price Performance
Inhibrx Biosciences stock traded down $0.49 during midday trading on Monday, reaching $23.96. The company had a trading volume of 15,672 shares, compared to its average volume of 97,400. The company has a market capitalization of $346.94 million, a P/E ratio of 0.21 and a beta of -0.04. Inhibrx Biosciences, Inc. has a 12-month low of $10.80 and a 12-month high of $24.76. The firm's fifty day simple moving average is $15.46 and its 200-day simple moving average is $13.91. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.12 and a quick ratio of 5.12.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, equities analysts anticipate that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current year.
Wall Street Analyst Weigh In
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx Biosciences in a research report on Thursday, May 15th.
Get Our Latest Research Report on Inhibrx Biosciences
About Inhibrx Biosciences
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
